Initial Statement of Beneficial Ownership (3)
December 23 2020 - 5:04PM
Edgar (US Regulatory)
FORM 3
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES
|
OMB APPROVAL
OMB Number:
3235-0104
Estimated average burden hours per response...
0.5
|
|
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
|
|
1. Name and Address of Reporting Person
*
Ragosa Mark |
2. Date of Event Requiring Statement (MM/DD/YYYY)
12/17/2020
|
3. Issuer Name and Ticker or Trading Symbol
Kiniksa Pharmaceuticals, Ltd. [KNSA]
|
(Last)
(First)
(Middle)
CLARENDON HOUSE, 2 CHURCH STREET |
4. Relationship of Reporting Person(s) to Issuer (Check all applicable)
_____ Director _____ 10% Owner ___X___ Officer (give title below) _____ Other (specify below) Interim CFO / |
(Street)
HAMILTON, D0 HM 11
(City)
(State)
(Zip)
| 5. If Amendment, Date Original Filed(MM/DD/YYYY)
| 6. Individual or Joint/Group Filing(Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
|
Table I - Non-Derivative Securities Beneficially Owned
|
1.Title of Security (Instr. 4) | 2. Amount of Securities Beneficially Owned (Instr. 4) | 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | 4. Nature of Indirect Beneficial Ownership (Instr. 5) |
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
|
1. Title of Derivate Security (Instr. 4) | 2. Date Exercisable and Expiration Date (MM/DD/YYYY) | 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) | 4. Conversion or Exercise Price of Derivative Security | 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5) | 6. Nature of Indirect Beneficial Ownership (Instr. 5) |
Date Exercisable | Expiration Date | Title | Amount or Number of Shares |
Share Option | (1) | 5/22/2028 | Class A Common Shares | 18299 | $18.00 | D | |
Share Option | (2) | 9/19/2028 | Class A Common Shares | 20000 | $30.93 | D | |
Share Option | (3) | 3/3/2029 | Class A Common Shares | 12000 | $17.92 | D | |
Share Option | (4) | 9/16/2029 | Class A Common Shares | 12000 | $8.83 | D | |
Share Option | (5) | 3/12/2030 | Class A Common Shares | 20000 | $15.52 | D | |
Share Option | (6) | 9/9/2030 | Class A Common Shares | 22000 | $15.50 | D | |
Restricted Share Units | (7) | (7) | Class A Common Shares | 4404 | (8) | D | |
Explanation of Responses: |
(1) | The option vested and became exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in thirty-six equal monthly installments thereafter. The vesting commencement date is May 10, 2018. |
(2) | The option vested and became exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in thirty-six equal monthly installments thereafter. The vesting commencement date is September 20, 2018. |
(3) | The option vested and became exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in thirty-six equal monthly installments thereafter. The vesting commencement date is March 4, 2019. |
(4) | The option vested and became exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in thirty-six equal monthly installments thereafter. The vesting commencement date is September 17, 2019. |
(5) | The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in thirty-six equal monthly installments thereafter. The vesting commencement date is March 13, 2020. |
(6) | The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in thirty-six equal monthly installments thereafter. The vesting commencement date is September 10, 2020. |
(7) | The Restricted Share Units (RSU) will vest in a single installment on December 31, 2020, subject to the Reporting Person's continuous employment or service to the Issuer or any of its subsidiaries on the vesting date; there is no expiration date for the RSU. |
(8) | Each Restricted Share Unit represents a contingent right to receive one Class A Common Share of the Issuer. |
Remarks: Exhibit 24 - Power of Attorney. |
Reporting Owners
|
Reporting Owner Name / Address | Relationships |
Director | 10% Owner | Officer | Other |
Ragosa Mark CLARENDON HOUSE 2 CHURCH STREET HAMILTON, D0 HM 11 |
|
| Interim CFO |
|
Signatures
|
/s/ Mark Ragosa | | 12/23/2020 |
**Signature of Reporting Person | Date |
Kiniksa Pharmaceuticals (NASDAQ:KNSA)
Historical Stock Chart
From Aug 2024 to Sep 2024
Kiniksa Pharmaceuticals (NASDAQ:KNSA)
Historical Stock Chart
From Sep 2023 to Sep 2024